Coronavirus Update: Once Written Off, Roche's Actemra Finally Gets EUA In COVID-19
Plus mRNA Vaccines To Carry Myocarditis Warning
Actemra finally gains an emergency use authorization, Lilly's antibodies withdrawn again amid Delta variant concerns, plus Latin America’s belief in an anti-parasite drug in COVID-19 could soon be punctured.
You may also be interested in...
While some cancer centers report sufficient stocks of the drug, they have already been turning to potential alternatives due to supply issues that could last for weeks or months.
Pfizer and BioNTech sent in Phase I data for a third dose of BNT162b2 to support future licensure, Gritstone bio will work with CEPI to develop its second-generation vaccine in South Africa and other areas, and Roche Genentech expects a shortage of the drug Actemra to last for several weeks amid a surge in cases.
Three authorized products currently used for arthritis and other conditions have now been filed for approval in Europe for treating people with severe COVID-19.